Real-World Evidence of Atezolizumab Efficacy as Part of First-Line Treatment for Extensive-Stage SCLC in Bulgaria
: Real-world evidence regarding PFS and treatment response generally align with the efficacy of adding atezolizumab to first-line extensive-stage SCLC treatment reported in the IMpower133 trial, while reflecting differences that may arise in routine clinical practice.
Authors
- Bozhil Robev
- Jeliazko Arabadjiev (ORCID: https://orcid.org/0000-0003-2440-2760)
- Tanya Zlatanova (ORCID: https://orcid.org/0000-0002-2456-2994)
- Assen Dudov (ORCID: https://orcid.org/0009-0008-4678-8629)
- Manoela Manova (ORCID: https://orcid.org/0000-0002-8749-7974)
- Daniel Penchev (ORCID: https://orcid.org/0009-0001-9971-9466)
- Velko Minchev
- Rositsa Krasteva
- Nikolay Conev (ORCID: https://orcid.org/0000-0001-5267-0354)
- Boryana Ivanova (ORCID: https://orcid.org/0000-0003-2466-9254)
- Ivan Tonev (ORCID: https://orcid.org/0000-0003-4399-3447)
- Krassimir Koynov (ORCID: https://orcid.org/0000-0002-7867-3462)
- Natalia Chilingirova
- T. I. Georgiev
- Alexandra Savova (ORCID: https://orcid.org/0000-0003-4579-5524)
- A. Rangelov
- Mila Petrova
Institutions
- Tokuda Hospital (BG)
- Medical University Plovdiv (BG)
- Medical University of Sofia (BG)
- Acibadem City Clinic (BG)
- University Hospital St. Marina (BG)
- Medical Center Hospital (US)
- University Hospital St. Ivan Rilski (BG)
- National Center of Infectious and Parasitic Diseases (BG)
- Medical University Pleven (BG)
- Sofia University "St. Kliment Ohridski" (BG)
Publication Details
- Journal
- Cancers
- Published
- 2026-04-01
- DOI
- https://doi.org/10.3390/cancers18071129
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission